|Bid||37.33 x 1800|
|Ask||37.40 x 800|
|Day's Range||36.97 - 39.79|
|52 Week Range||21.50 - 63.13|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for RXDX
Shares of Prometheus Biosciences (NASDAQ: RXDX) were down more than 12% this week as of Friday morning, according to data from S&P Global Intelligence. The clinical-stage biotech company specializes in immunotherapies with a focus on inflammatory bowel disease (IBD). Prometheus' lead therapy in its pipeline is IBD drug PRA023.
Prometheus Biosciences ( NASDAQ:RXDX ) Third Quarter 2022 Results Key Financial Results Net loss: US$37.3m (loss...
Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of -1.12% and 26.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?